MMOVE project: Make MRD valued & endorsed
MRD (minimal residual disease) testing is a more sensitive measure compared with traditional definitions of clinical response which helps to detect residual tumor cells in the bone marrow and to better discriminate patients at risk for relapsing accordingly.
MMOVE project aims to make MRD measurement available for multiple myeloma patients in Belgium.
To achieve this goal, the BHS Multiple Myeloma-workgroup initiated a cooperation with Janssen-Cilag NV.
Discover more about the project and consult the workflows: